REGENXBIO Inc. (NASDAQ:RGNX)’s traded shares stood at 0.33 million during the last session, with the company’s beta value hitting 1.05. At the close of trading, the stock’s price was $31.67, to imply a decrease of -2.52% or -$0.82 in intraday trading. The RGNX share’s 52-week high remains $50.26, putting it -58.7% down since that peak but still an impressive 16.64% since price per share fell to its 52-week low of $26.40. The company has a valuation of $1.40B, with an average of 0.87 million shares in intraday trading volume over the past 10 days and average of 476.82K shares over the past 3 months.
Analysts have given a consensus recommendation of an Overweight for REGENXBIO Inc. (RGNX), translating to a mean rating of 2.00. Of 8 analyst(s) looking at the stock, 0 analyst(s) give RGNX a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 6 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$1.3.
REGENXBIO Inc. (NASDAQ:RGNX) trade information
After registering a -2.52% downside in the last session, REGENXBIO Inc. (RGNX) has traded red over the past five days. The stock hit a weekly high of 39.85 this Friday, 10/08/21, dropping -2.52% in its intraday price action. The 5-day price performance for the stock is -21.38%, and -5.86% over 30 days. With these gigs, the year-to-date price performance is -30.18%. Short interest in REGENXBIO Inc. (NASDAQ:RGNX) saw shorts transact 3.1 million shares and set a 5.64 days time to cover.
Analysts on Wall Street suggest a consensus price target of $65.13, implying an increase of 51.37% to the stock’s current value. The extremes give us $44.00 and $100.00 for target low and target high price respectively. As such, RGNX has been trading -215.76% off suggested target high and -38.93% from its likely low.
REGENXBIO Inc. (RGNX) estimates and forecasts
Revenue is forecast to shrink -665.20% this quarter before jumping 11.30% for the next one. The rating firms project that company’s revenue will shrink -35.20% compared to the previous financial year.
Revenue forecast for the current quarter as set by 4 analysts is $31.49 million. Meanwhile, for the quarter ending Dec 2021, a total of 4 analyst(s) estimate revenue growth to $45.58 million.Earnings reports from the last fiscal year show that sales brought in $21.37 million and $21.45 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 47.40% before jumping 112.50% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -25.20% for the past 5-year period. While 2021 is set for a -15.60% return in earnings, projections for the next 5 years are at 2.00% annually.
REGENXBIO Inc. has its next earnings report out between November 02 and November 08. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. REGENXBIO Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
REGENXBIO Inc. (NASDAQ:RGNX)’s Major holders
REGENXBIO Inc. insiders hold 12.52% of total outstanding shares, with institutional holders owning 86.34% of the shares at 98.69% float percentage. In total, 86.34% institutions holds shares in the company, led by Blackrock Inc. As of Jun 29, 2021, the company held over 6.2 million shares (or 14.56% of shares), all amounting to roughly $240.91 million.
The next major institution holding the largest number of shares is Vanguard Group, Inc. (The) with 3.94 million shares, or about 9.26% of shares outstanding. As of the market price on Jun 29, 2021, these shares were worth $153.22 million.
We also have iShares Core S&P Smallcap ETF and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF as the top two Mutual Funds with the largest holdings of the REGENXBIO Inc. (RGNX) shares. Going by data provided on Aug 30, 2021, iShares Core S&P Smallcap ETF holds roughly 2.33 million shares. This is just over 5.48% of the total shares, with a market valuation of $75.35 million. Data from the same date shows that the other fund manager holds a little less at 1.2 million, or 2.83% of the shares, all valued at about 38.87 million.